Literature DB >> 19926109

Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes.

Stephan Maersch1, Anke Huber, Hildegard Büning, Michael Hallek, Luca Perabo.   

Abstract

Therapeutic gene transfer by adeno-associated virus of serotype 2 (AAV-2) vectors is hampered in patients with pre-existing immunity. Molecular engineering was recently used to identify key immunogenic amino acid residues of the viral capsid and generate mutants with decreased antibody recognition. Here we explored the importance of finely tuning amino acid identity at immunogenic sites to optimize vector phenotype. A capsid library was generated by codon randomization at five positions where substitutions were shown to yield antibody evading phenotypes. Screening this library to isolate immune-escaping mutants allowed an exhaustive scan of combinations of the 20 natural amino acids at each position and yielded variants that remained infectious when incubated with serum or IVIG concentrations that completely neutralize AAV-2. Clones obtained replacing different residues at the same positions displayed strikingly different phenotypes, demonstrating that a precise choice of amino acid substitutions is fundamental to optimize immune-escaping, packaging ability, infectivity and tropism. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19926109     DOI: 10.1016/j.virol.2009.10.021

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  28 in total

1.  Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.

Authors:  Carole E Harbison; Wendy S Weichert; Brittney L Gurda; John A Chiorini; Mavis Agbandje-McKenna; Colin R Parrish
Journal:  J Gen Virol       Date:  2011-11-09       Impact factor: 3.891

Review 2.  Parkinson's disease: gene therapies.

Authors:  Philippe G Coune; Bernard L Schneider; Patrick Aebischer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 3.  E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution.

Authors:  Dirk Grimm; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2015-09-21       Impact factor: 11.454

Review 4.  The AAV vector toolkit: poised at the clinical crossroads.

Authors:  Aravind Asokan; David V Schaffer; R Jude Samulski
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

5.  Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.

Authors:  Chengwen Li; Nina Diprimio; Dawn E Bowles; Matthew L Hirsch; Paul E Monahan; Aravind Asokan; Joseph Rabinowitz; Mavis Agbandje-McKenna; R Jude Samulski
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

6.  A NEW RECOMBINANT ADENO-ASSOCIATED VIRUS (AAV)-BASED RANDOM PEPTIDE DISPLAY LIBRARY SYSTEM: INFECTION-DEFECTIVE AAV1.9-3 AS A NOVEL DETARGETED PLATFORM FOR VECTOR EVOLUTION.

Authors:  Kei Adachi; Hiroyuki Nakai
Journal:  Gene Ther Regul       Date:  2010-10

7.  Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors.

Authors:  M Trepel; J Körbelin; E Spies; M B Heckmann; A Hunger; B Fehse; H A Katus; J A Kleinschmidt; O J Müller; S Michelfelder
Journal:  Gene Ther       Date:  2015-06-02       Impact factor: 5.250

Review 8.  Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.

Authors:  Vedell Louis Jeune; Jakob A Joergensen; Roger J Hajjar; Thomas Weber
Journal:  Hum Gene Ther Methods       Date:  2013-04-03       Impact factor: 2.396

Review 9.  Systemic delivery of adeno-associated viral vectors.

Authors:  Dongsheng Duan
Journal:  Curr Opin Virol       Date:  2016-07-25       Impact factor: 7.090

10.  Structure of neurotropic adeno-associated virus AAVrh.8.

Authors:  Sujata Halder; Kim Van Vliet; J Kennon Smith; Thao Thi Phuong Duong; Robert McKenna; James M Wilson; Mavis Agbandje-McKenna
Journal:  J Struct Biol       Date:  2015-08-31       Impact factor: 2.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.